Summary
McKesson Corporation reported a strong first quarter for fiscal year 2004, with revenues increasing 21% to $16.5 billion and net income growing 33% to $155.6 million. This growth was primarily driven by the Pharmaceutical Solutions segment, which represents over 94% of total revenue. The company saw significant year-over-year improvements in operational efficiency and profitability, evidenced by a 36% increase in diluted earnings per share, which rose to $0.53. The balance sheet also strengthened, with total assets growing and a notable increase in net cash provided by operating activities compared to the prior year. The company also continued its share repurchase program, buying back $75.3 million worth of its common stock in the quarter. While McKesson faces ongoing litigation related to past accounting improprieties, the company is actively managing its operations and financial condition. The report highlights a positive trend in liquidity and capital resources, with a reduced debt-to-capital ratio, indicating a sound financial footing.
Key Highlights
- 1Revenue increased 21% year-over-year to $16.5 billion, driven by strong performance in the Pharmaceutical Solutions segment.
- 2Net income grew 33% to $155.6 million, with diluted earnings per share up 36% to $0.53.
- 3Operating expenses decreased by 2% year-over-year, indicating improved efficiency.
- 4Net cash provided by operating activities was $43.3 million, a significant improvement from a negative $197.5 million in the prior year's comparable quarter.
- 5The company repurchased $75.3 million of its common stock in the quarter as part of its ongoing share repurchase program.
- 6The debt-to-capital ratio improved to 21.0% from 21.6% in the previous quarter, demonstrating a strengthening balance sheet.